Sartorius Stedim Biotech is a leading provider of cell line development and upstream process development services for large-scale protein production of biopharmaceuticals in mammalian (CHO) cells. For this purpose, we have devised a unique cell line development technology platform made up of 4 key components:   Expression Vector Host Cell Line CHO Media System Upstream Process Design   Together they deliver high yielding, stable cell lines and robust, simple, fed-batch processes for the biopharmaceutical market. The CellcaCHO Expression Platform is an easily accessible, scalable and robust system that takes your product from DNA to RCB in just 4 months.

Since inception, Sartorius Stedim Biotech has delivered over 76 CHO cell lines expressing various biologics, which have progressed to clinical trials and market approval including:   mAbs (IgG1, IgG4, IgG2) Fc-fusion proteins Fab-related products Bispecific antibodies Biosimilars antibodies   We have extensive experience in custom cell line development projects, including difficult to express proteins.   The CellcaCHO Expression Platform consistently delivers production processes withtitres of 3 g/L or more, which is evidenced in our successful track record: